{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "RLYB",
  "name": "Rallybio Corporation",
  "url": "https://orbyd.app/dossiers/RLYB/",
  "json_url": "https://orbyd.app/dossiers/RLYB.json",
  "status": "DORMANT",
  "current_conviction": "MEDIUM",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Corrected cash math changes the read: the $50.0M Candid break fee received 2026-05-04 landed after the 3/31 balance sheet, so ~$97M gross cash sits against 5.30M shares (~$18.3/sh) versus a $16.42 quote. Buyer gets the cash distribution near par with the CVR and 2.8% Avenzo stub close to free. Event-pinned to a Q4 close, no momentum leg.",
  "invalidation_trigger": "A weekly close below $13 breaks the sum-of-parts read — that sits under any plausible distribution floor given the 2026-05-04 $50.4M receipt and implies the market is pricing a deal break. Secondary: the ~2026-08-06 Q2 print showing pre-closing net cash under ~$70M erases the margin of safety at current prices.",
  "catalyst_date": "2026-08-06",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "m-and-a-special-situations",
    "precision-biotech-therapeutics",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-06-01: Reverse merger w/ private Avenzo Therapeutics + $215M PIPE; combined co. Rebrands AVZO, closes Q4 2026. Legacy RLYB = cash distribution + 1 CVR/share (REV102/Recursion + legacy assets) + 2.8% stub ($15M implied vs Avenzo $300M / financing $215M).",
    "2026-06-01: All-stock reverse merger with private Avenzo Therapeutics + $215M oversubscribed concurrent PIPE; combined co. Rebrands Avenzo, trades as AVZO, expected close Q4 2026. Boards unanimously approved.",
    "2026-03-01: merger agreement with Candid Therapeutics. 2026-05-03: Candid terminated to accept a UCB deal (Candid acquired by UCB for up to $2.2B). 2026-05-04: Rallybio paid $50.0M parent termination fee + $0.4M expense reimbursement.",
    "2026-06-01: all-stock reverse merger with private Avenzo Therapeutics + $215M oversubscribed concurrent PIPE. Combined co rebrands Avenzo Therapeutics, trades AVZO, expected close Q4 2026.",
    "PIPE syndicate: Blackstone Multi-Asset Investing, accounts advised by T. Rowe Price Investment Management, Vivo Capital, OrbiMed, Affinity Asset Advisors, ADAR1 Capital Management.",
    "Legacy holders receive three things: (1) cash distribution of substantially all pre-closing net cash, (2) one non-transferable CVR per share on net proceeds from the Recursion membership-interest purchase (REV102) and other legacy-asset dispositions, one-year disposition window post-close, (3) ~2.8% stub.",
    "1-for-8 reverse split effective 2026-02-06 for Nasdaq listing compliance, executed while winding down and before either merger. Share count now 5.30M.",
    "Position sizing must assume no exit into a deal-break print.",
    "Merger agreement requires the Rallybio special meeting no later than 45 calendar days after the registration statement is declared effective. No record date or meeting date public as of 2026-07-19.",
    "Avenzo pipeline: AVZO-021 (CDK2, ASCO 2026-06-01: 5.3mo mPFS in heavily-pretreated HR+/HER2-, median 4 prior lines), AVZO-023 (CDK4), AVZO-1418 (EGFR/HER3 ADC), AVZO-103 (Nectin4/TROP2 ADC). Funded into late 2028.",
    "Beta -0.89. Uncorrelated to XBI/SPY; price is a function of deal-completion odds and the cash number.",
    "Re-tag and relink this dossier to AVZO after the Q4 2026 close. The oncology story is an AVZO story on a fresh post-close setup."
  ],
  "body_markdown": "\nde# RLYB — Rallybio Corporation\n\n## Current Thesis\nThe material fact the last read underweighted: on **2026-05-04 Rallybio collected a $50.0M parent termination fee plus $0.4M of expense reimbursement** after Candid Therapeutics walked from its 2026-03-01 merger agreement to take a UCB deal (Candid terminated 2026-05-03). That cash landed *after* the 3/31/26 balance-sheet date, so every net-cash figure lifted from the Candid-era S-4 — the ~$35.8M as of 2026-04-15, the ~$37.5M carried in earlier deal math — is pre-windfall and understates the distributable pile by roughly $50M.\n\nRerun the arithmetic. Q1 close carried **$41.3M cash + $5.5M marketable securities = $46.8M**; add $50.4M and the gross sits near **$97M against 5.30M shares outstanding**, or ~$18.3/share before burn. Against a **$16.42 quote (2026-07-17, +2.88%)** and an **$87.0M market cap**, a buyer is paying at or near the cash distribution alone and receiving the CVR and the 2.8% stub for close to nothing. That is a sum-of-parts trade with a defined event calendar — no accelerating narrative, no momentum leg, and a Q4 2026 close that locks capital for roughly a quarter and a half.\n\n## Bull Case\n- **2026-05-04:** $50.0M termination fee + $0.4M expenses received. A busted deal paid Rallybio more than half its then-market cap, and the cash flows to legacy holders because the merger agreement has the company \"distribute substantially all of its pre-closing net cash to its pre-closing stockholders.\"\n- **2026-03-31 balance sheet:** $41.3M cash + $5.5M securities. Stacked with the fee, gross pre-burn cash of ~$97M / 5.30M shares ≈ $18.3 per share, against a $16.42 tape. Trailing-twelve-month net loss of only **$7.82M** shows a cost base already gutted through the 2025 strategic review, so quarterly burn between here and close is small relative to the pile.\n- **Free CVR per share:** entitles holders to net proceeds from the Recursion membership-interest purchase covering the REV102 program plus disposition of other legacy assets, with a one-year post-closing disposition window under the CVR construct. Costs nothing at these prices; pays zero if nothing sells.\n- **Blue-chip $215M PIPE, oversubscribed:** Blackstone, accounts advised by T. Rowe Price, Vivo Capital, OrbiMed, Affinity Asset Advisors and ADAR1 Capital Management. Financing fall-through risk is low, which is the single largest determinant of whether the 2.8% stub converts into a listed AVZO share at all.\n- **Reverse break protection:** Avenzo owes Rallybio **$20.0M** on certain terminations ($8.0M after the End Date) plus up to $750K of expenses, against only $600K flowing the other way. Asymmetric, and this management has already banked one break fee.\n- **2026-06-01 ASCO:** AVZO-021, a selective CDK2 inhibitor, produced 5.3-month median PFS in heavily-pretreated HR+/HER2− breast cancer (median four prior lines) with low-incidence GI and heme tolerability. The $215M funds four programs into late 2028 across multiple Phase 1 readouts and several Phase 2 starts.\n\n## Bear Case\n- **The net-cash figure is inferred, not disclosed.** $97M gross is arithmetic on a 3/31 balance sheet plus a dated receipt. Deduct roughly three quarters of shell opex and Avenzo transaction and legal costs and a $75–85M distributable range is the realistic band, i.e. **$14–16 per share**. At $16.42 the discount is thin to nonexistent at the low end of that band.\n- **Legacy holders own 2.8% of the future.** Implied valuations of $15M for Rallybio and $300M for Avenzo drive the exchange ratio; the $215M financing takes 40.6%, implying ~$530M pro-forma equity. The stub is worth ~$2.83/share at deal marks and small-cap reverse-merger stubs routinely settle below PIPE price on the first free-trading tape.\n- **The 2.8% is struck assuming ~$0 net cash at close** because the cash is distributed first. Any leakage — higher deal costs, a larger retained reserve, an escrow against legacy liabilities — comes straight out of the distribution, not out of the stub.\n- A position of any size cannot be exited into a deal-break print.\n- **No proxy record date or special-meeting date is public** as of 2026-07-19. The merger agreement requires the Rallybio meeting no later than 45 calendar days after the registration statement is declared effective, so the calendar is constrained but not yet dated.\n- **The move already happened.** From a 52-week low of $3.20 to $16.42 is a five-bagger driven by two discrete events, both banked.\n\n## Setup & Price Structure\nPrice **$16.42** on 2026-07-17 (+2.88% that session), inside a 52-week range of **$3.20–$17.57** and sitting in the top ~6% of it. Market cap $87.0M on 5.30M shares — share count reflects the **1-for-8 reverse split effective 2026-02-06**, executed for Nasdaq listing compliance while the company was winding down, before either deal existed.\n\nSeven weeks after the 2026-06-01 announcement the stock has not round-tripped; it has ground from ~$15.71 (2026-06-25) to ~$16.06 (2026-06-29) to $16.42, a slow upward drift on thin volume rather than a momentum impulse. That is what an arb book accumulating toward a cash floor looks like. Beta of **-0.89** confirms the obvious: this ticker does not trade with the tape.\n\nThe structural read is a compressed range beneath the $17.57 high with a soft floor wherever the eventual distribution prints. There is no moving-average setup worth trading here and no volume signature to follow — the chart is a valuation band, and the band's width is the uncertainty in the net-cash number.\n\n## Catalyst Calendar (next 30 days)\n\n- **Undated, legacy-asset dispositions:** any announced sale of REV102-related interests or other legacy assets marks the CVR before close rather than after.\n- **Q4 2026 (no fixed date), transaction close:** conditioned on both stockholder votes, S-4 effectiveness, Nasdaq listing approval and completion of the $215M financing. Falls outside this window.\n\n## Elapsed catalysts\n\n- **~2026-08-06 (est.), Q2 2026 results:** the decisive item. The first balance sheet to carry the $50.4M receipt and the first hard read on burn since the Candid break. This print converts the $75–85M distributable estimate into a number. *(passed 3d ago)*\n- **Ongoing, S-4 / proxy-prospectus effectiveness:** a registration statement covering the Avenzo transaction is on file. Effectiveness triggers the 45-day clock to the Rallybio special meeting and should disclose the assumed net cash, the final reverse-split ratio and the record date. No effectiveness date is public as of 2026-07-19. *(passed 21d ago)*\n\n## What Would Change Our Mind\nA **weekly close below $13** breaks the read — that level sits under any plausible distribution floor consistent with the 2026-05-04 receipt and would mean the market is pricing either a deal break or a distribution far smaller than the balance sheet implies. Second condition: if the ~2026-08-06 Q2 print shows pre-closing net cash under roughly $70M, the margin of safety is gone at $16.42 and the name reverts to a fully-valued stub-plus-lottery-ticket.\n\nOn the other side, a disclosed net cash figure above ~$85M with a dated special meeting turns this from a fair-value hold into a genuine discount, and would justify sizing up rather than probing. A second termination — Avenzo walking and paying the $20.0M fee — is not a disaster case here; it returns the vehicle to a cash shell holding more cash per share than it did in March.\n\n## Correlation Notes\nBeta of -0.89 makes this a poor XBI or SPY proxy; the price is a function of deal-completion odds and a cash number, not biotech risk appetite. It correlates with the reverse-merger-shell cohort — busted clinical-stage names re-rating off strategic reviews — and with financing conditions for private oncology, since a PIPE that cannot fund is the main path to a broken deal. It does not correlate with the CDK2/CDK4 competitive landscape in any tradeable way today: that exposure only arrives with the 2.8% stub after close.\n\nThe oncology story is an AVZO story. Anyone underwriting AVZO-021, AVZO-023, the AVZO-1418 EGFR/HER3 ADC or the AVZO-103 Nectin4/TROP2 ADC should wait for the post-close listing and a fresh setup rather than buying 2.8% of it wrapped inside a cash-distribution vehicle. This dossier should re-tag to AVZO once the merger closes.",
  "first_seen": "2026-05-07",
  "last_analyzed": "2026-07-19T11:28:17+00:00",
  "last_synthesized": "2026-07-19",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}